Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (April 21st Preview)
-
Lilly to scale in vivo CAR-T with Kelonia buyout
Eli Lilly announced it will acquire Kelonia Therapeutics for up to $7 billion, paying $3.25 billion upfront with additional milestone payments tied to clinical, regulatory and commercial outcomes. The deal is expected to close in the second half of 2026. Kelonia is developing KLN-1010, an intravenously delivered, lentiviral in vivo CAR-T approach aimed at generating BCMA-targeting T cells inside the patient for multiple myeloma. Lilly positioned the program as a way to reduce the manufacturing complexity and patient-access barriers associated with ex vivo CAR-T. Lilly’s acquisition follows earlier in vivo CAR-T moves, and the company said it plans to expand beyond multiple myeloma to additional hematologic cancers and potentially solid tumors. The transaction underscores how major pharma is doubling down on in-body genetic medicine platforms as next-generation cell therapy engines. —
-
iGPS Kelonia purchase reframes Lilly’s in-vivo pipeline bets
Further coverage of the acquisition highlights how Kelonia’s in vivo gene placement system (iGPS) adds another clinical-stage asset to Lilly’s genetic medicines roadmap. The buyer’s broader objective is to build a scalable “onetime infusion” CAR-T engine that can be delivered in routine clinical settings. Kelonia’s lead program, KLN-1010, is in Phase I development for relapsed/refractory multiple myeloma (NCT07075185). The companies framed early data around minimal residual disease (MRD) negativity in the earliest cohort and pointed to an FDA-cleared IND that enables multi-site expansion in the U.S. Investor commentary in the reporting also tied the transaction to a high-profile return for early backers, reinforcing how in vivo CAR-T has attracted capital as a potential operational advantage over conventional ex vivo workflows.
-
CAR-T pivots to earlier disease stage in smoldering myeloma
Dana-Farber investigators reported early phase results from CAR-PRISM testing CAR-T in high-risk smoldering multiple myeloma, aiming to intercept disease before it becomes active. The dataset was presented as part of an emerging shift toward moving immunotherapy earlier along the disease continuum. The trial approach combines intensive monitoring with CAR-T deployment in a precancerous stage, with the intent to drive deep molecular responses. Reporting described complete clearance of detectable myeloma cells in all treated patients in the cohort. If replicated in larger studies, the results could influence how companies and clinicians think about endpoints and treatment goals for pre-malignant plasma cell disorders, where standard options often focus on long-term disease suppression rather than deep eradication.
-
NEOPRISM-CRC tests short immunotherapy before bowel cancer surgery
Researchers at University College London and University College London Hospitals reported follow-up results from NEOPRISM-CRC, a trial testing a short course of immunotherapy before surgery for a subset of bowel cancer patients. The study is positioned as an attempt to deepen response while keeping the perioperative workflow intact. The new readout reported “zero relapses” in the follow-up period, an outcome that would be notable in a setting where perioperative immunotherapy is still being defined and patient selection remains a key question. The NEOPRISM-CRC strategy is designed to bypass longer, conventional sequencing by delivering systemic immune priming prior to tumor resection. Clinically, perioperative trial designs are increasingly used to generate tissue and response biology that can help refine future immunotherapy combinations and biomarkers. UCL and UCLH said the results support continued evaluation of the pre-surgery approach.
-
CRISPR screens map human genes that govern HIV infection in primary CD4+ T cells
Gladstone Institutes and UCSF published a genome-wide CRISPR map of host factors that either promote or restrict HIV infection in primary human CD4+ T cells. Published in Cell, the work addresses the gap between earlier studies in immortalized lines and the biology of the cells HIV actually infects in vivo. The team reported that years of optimization improved infection rates from ~1–2% to roughly 70%, enabling orthogonal genome-wide CRISPR activation (CRISPRa) and knockout (CRISPRn) screens. The screens tested nearly every human gene to reveal both viral dependencies and antiviral defenses. Lead author Ujjwal Rathore and senior author Alex Marson described the resulting “blueprint” of the host–virus interface, including genes previously unknown to influence infection outcomes in primary T cells. The dataset is expected to feed target prioritization for antiviral and immune-modulating strategies. —
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.